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Abstract
Background
Application of mesenchymal stem/stromal cells (MSCs) in treating different disorders, in
particular osteo-articular diseases, is currently under investigation. We have already docu-
mented the safety of administrating human adipose tissue-derived stromal MSCs (hASCs)
in immunodeficient mice. In the present study, we investigated whether the persistence of
MSC is affected by the degree of inflammation and related to the therapeutic effect in two in-
flammatory models of arthritis.
Methodology/Principal Findings
We used C57BL/6 or DBA/1 mice to develop collagenase-induced osteoarthritis (CIOA) or
collagen-induced arthritis (CIA), respectively. Normal and diseased mice were administered
2.5×105 hASCs in the knee joints (IA) or 106 in the tail vein (IV). For CIA, clinical scores
were monitored during the time course of the disease while for CIOA, OA scores were as-
sessed by histology at euthanasia. Thirteen tissues were recovered at different time points
and processed for real-time PCR and Alu sequence detection. Immunological analyses
were performed at euthanasia. After IV infusion, no significant difference in the percentage
of hASCs was quantified in the lungs of normal and CIA mice at day 1 while no cell was de-
tected at day 10 taking into account the sensitivity of the assay, indicating that a high level
of inflammation did not affect the persistence of cells. In CIOAmice, we reported the thera-
peutic efficacy of hASCs at reducing OA clinical scores at day 42 when hASCs were not de-
tected in the joints. However, the percentage and distribution of hASCs were similar in
osteoarthritic and normal mice at day 1 and 10 after implantation indicating that moderate in-
flammation does not alter hASC persistence in vivo.
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Conclusions/Significance
While inflammatory signals are required for the immunosuppressive function of MSCs,
they do not enhance their capacity to survive in vivo, as evaluated in two xenogeneic
inflammatory pre-clinical models of arthritis.
Introduction
Mesenchymal stem or stromal cells (MSCs) are promising cells for regenerative medicine, based
on their differentiation, trophic or immunomodulatory properties [1]. MSCs originating from
bone marrow (BM-MSCs) or fat tissue (ASCs) are the most widely used in clinical trials for a
wide range of diseases. Depending on the diseases, MSCs may be systemically or locally injected.
For osteo-articular diseases, intravenous (IV) injection will be favored in case of systemic
diseases such as rheumatoid arthritis (RA) which is characterized by the concurrent inflammation
of several joints [2, 3]. In the case of osteoarthritis (OA), where only one or two joints are
affected, intra-articular (IA) injection of cells could likely be the most relevant option. Besides the
importance of the route of administration, priming of MSC by inflammatory signals is proposed
to be required for therapeutic efficacy, in particular for stimulating their immunosuppressive
effects [4].
An inflammatory pathological environment, as present in patients with dysregulated immune
functions, is known to induce MSC immunosuppressive functions, as recapitulated in vitro using
MSC induction with interferon (IFN)-γ and tumor necrosis factor (TNF)-α or interleukin (IL)-
1α or -1β [5]. A role of inflammatory signals onMSC activation was also suggested in one of our
previous studies reporting that in vitro coculture of hASCs with highly inflammatory chondro-
cytes from OA patients down-regulated the expression of several inflammatory molecules while
no effect was observed when chondrocytes expressed low or moderate levels of inflammatory
molecules [6]. This is further supported by recent findings that the protective effect of hASCs
was only observed in the collagenase-induced model of osteoarthritis when high synovial inflam-
mation was present at the time of injection[7]. In animal models of transplantation, MSCs were
effective in prolonging graft survival when injected before transplantation while they were not
when injected later on [8]. These observed differences may be due to distinct suppressive re-
sponses of MSCs in the absence or presence of inflammatory mediators. They may also be related
to a different survival rate of MSCs submitted to inflammatory stimuli.
We previously showed different survival time and biodistribution depending on the route
of administration using autologous human ASCs (hASCs) implantation in normal SCID/Bg
mice, which do not mount inflammatory response to foreign cells [9]. However, such studies
in immunodeficient mice do not take into account the pathological environment of diseases.
The role of the inflammatory milieu on the therapeutic efficacy of MSCs has been widely
claimed but whether it may also be related to a better cell survival has been poorly investigat-
ed in vivo. The main objective was to investigate whether the degree of inflammation may
influence the survival of MSCs since their capacity to escape the host immune response is
proposed to be related to a priming/activation step by the inflammatory environment. In the
present study, we therefore investigated the therapeutic efficacy and persistence of hASCs in
mice in the context of moderate or severe inflammation in murine models of collagenase-
induced osteoarthritis (CIOA) and collagen-induced inflammatory arthritis (CIA),
respectively.
Inflammation Does Not Affect ASC Survival
PLOS ONE | DOI:10.1371/journal.pone.0114962 January 5, 2015 2 / 13
Nationale pour la Recherche for support of the nation-
al infrastructure: “ECELLFRANCE: Development of a
national adult mesenchymal stem cell based therapy
platform” (ANR-11-INSB-005). Tigenix and
Farmacros got funding from the European Union’s
Seventh Programme for research, technological
development and demonstration under grant
agreement No 279174 to perform these studies. The
funders had no role in study design, decision to
publish, or preparation of the manuscript. EL and WD
are employees of TiGenix; JLB is employee of
FarmaCross-Iberica. TiGenix and FarmaCross-
Iberica provided support in the form of salaries for
authors EL, WD and JLB, but did not have any
additional role in the study design, decision to publish,
or preparation of the manuscript. The specific roles of
these authors are articulated in the ‘author contribu-
tions’ section.
Competing Interests: EL and WD are employees of
TiGenix; JLB is employee of FarmaCross-Iberica.
Tigenix and Farmacros got funding from the Europe-
an Union’s Seventh Programme for research, techno-
logical development and demonstration under grant
agreement No 279174 to perform these studies.
Other authors declare no conflict of interest. This
does not alter the authors’ adherence to PLOS ONE
policies on sharing data and materials.
Methods
Isolation and characterization of adipose tissue-derived mesenchymal
stem cells
Human samples were obtained from patients after informed consent as approved by the
French Ministry of Research and Innovation (approval DC-2010-1185) or the Spanish Ethics
Committee of reference (Clinica de la Luz Hospital) for the site of tissue procurement. hASCs
were isolated from normal donors undergoing plastic surgery after informed written consent
as described [10, 11]. Briefly, fat tissue was digested with collagenase at 37°C for 1h. The stro-
mal vascular fraction was plated in α-MEMmedium supplemented with 100U/ml penicillin/
streptomycin, 2mmol/mL glutamine and 10% fetal bovine serum. hASCs were characterized by
their immunophenotype (positive for CD13, CD73, CD90, CD105 and negative for CD11b,
CD14, CD31, CD34, CD45) and their trilineage potential of differentiation as published [10].
Cells were used before 14 population doublings.
CIOA animal model
Ten weeks old C57BL/6 male mice were obtained from Janvier (Saint-Berthevin). Animal ex-
perimentation was conducted in agreement with the Languedoc-Roussillon Regional Ethics
Committee on Animal Experimentation (approval CEEA-LR-10041). All surgery was per-
formed under isoflurane gas anesthesia, and all efforts were made to minimize suffering. Knee
joints were injected with 1 unit of type VII collagenase from Clostridium histolyticum (Sigma-
Aldrich, L’Isle d’Abeau) in 5ml of saline on days 0 and 2, as previously described [12]. On day
7, two groups of 10 mice received either saline (CIOA) or hASCs (2.5×105 cells/7ml; CIOA+
ASC), which were administered in both knee joints. Animals from each group were sacrificed
at day 42 for histological evaluation of the disease and blood recovery. In parallel, either normal
or CIOA groups of 30 animals received 2.5×105 cells hASCs/7ml on day 7. Euthanasia was per-
formed on 10 animals at day 1, 10 or 30 for DNA analysis.
CIA animal model
Animal experimentation was conducted in agreement with the Spanish Real Decreto 223/1988,
the Directive 86/609/CEE and also Directive 2010/63/EU on the protection of animals used for
scientific purposes for the curative approach. For the preventive approach, authorization was
obtained from the Languedoc-Roussillon Regional Ethics Committee on Animal Experimenta-
tion (approval CEEA-LR-11052). All procedures were designed to minimize suffering. CIA
was induced in male DBA/1 mice aged 7–9 weeks purchased from Janvier (Saint-Berthevin).
Immunization and boost were performed by injecting 100ml of chicken collagen II in Freund’s
complete and incomplete adjuvant (2 mg/ml) subcutaneously in the back respectively, at day 0
and 21. For the preventive approach, groups of 8 mice were infused IV with saline or hASCs
(106 cells/100ml saline) at day 18 and day 24. For the curative approach, saline or hASCs
(106 cells/100ml saline) were administered IV in groups of 10 mice when the arthritis score was
2–4 [13, 14]. In both approaches, arthritis score was determined by measurement of hind paw
swelling and inflammatory reaction for hind and fore paws for 10 or 13 days after the last injec-
tion. Clinical score was assessed using the following system: grade 0, no swelling; grade 1:
0.1 mm increase of paw swelling or 1 digit; grade 2: 0.2 mm paw swelling increase and two
groups of joints inflamed; grade 3: extensive swelling ( 0.3 mm) with severe joint deformity
and more than two groups of joints inflamed; grade 4: pronounced swelling ( 0.45 mm)
with pronounced joint deformity. A total score of 16 was recorded for each mouse. In parallel,
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106 hASCs were injected in one group of 30 mice scored 2–4 CIA or one group of 30 normal
age-matched mice at the same time. Mice were euthanatized on day 1, 10, 30 for DNA analysis.
Organ recovery
At sacrifice, 13 organs (lung, heart, kidney, spleen, Tibialis anteriormuscle, brain, inguinal fat
pad, stomach, intestine, liver, testis or ovaries, blood, total knee joint) were recovered and fro-
zen at −80°C for DNA analysis, as described [9]. For the CIOA model, one hind paw was sec-
tioned at the epiphyses of both femur and tibia to recover total knee joint exempt of muscle
tissue for DNA analysis. The second hind paw was sectioned at half of the femur and at the
ankle joint and fixed in 3.7% formaldehyde for histology.
DNA extraction and real time PCR
All or part of the organs were mechanically dissociated and DNA extraction was performed
using the DNeasy Blood & Tissue kit (Qiagen, Courtaboeuf) [9]. Real time PCR (qPCR) was
performed on 25ng DNA in 10ml that contained 5ml of DNAMaster SYBR Green I kit (Roche
Diagnostics, Meylan) and 0.05mM primers. Sequences of primers and PCR conditions were as
described [9]. Standard curves were generated by adding ten-fold serial dilutions of hASCs in
murine MSCs (106 total cell number). Results were expressed as the percentage of hASCs per
organ or blood (total blood evaluated at 1.5ml/mouse) and limit of detection was estimated to
be 0.005% hASCs of total cells [9].
Cytokine measurement
Murine MCP-1 and S100A9 alarmin concentrations were determined in sera of CIOA mice at
euthanasia by specific sandwich enzyme-linked immunosorbent assay (ELISA) as recom-
mended by the supplier (R&D Systems).
Histological analysis
Knee joints from CIOAmice were embedded in paraffin and cut in sections of 7mm, stained with
Safranin O-Fast green for analysis of cartilage damage. Cartilage damage was scored using the
modified Pritzker OARSI score [15]. In brief, lateral and medial tibia plateaus and femur condyles
were scored for the grade of cartilage destruction (0–6) and the extent of damaged cartilage sur-
face (0–5). For each location of a mouse knee, these scores were multiplied and an average of 3
scores corresponding to 3 sections separated by a 140mm thickness formed the OA cartilage score.
T lymphocyte subset analysis by flow cytometry
Splenocytes and lymph node cells were isolated from CIA mice, as described previously [14].
For intracellular cytokine detection, cells were stimulated with PMA (50 ng/ml), ionomycin
(1 mg/ml) and brefeldin A (10 mg/ml) for 4 h. Specific antibodies against mouse CD4 and CD25
were then added to the cells for 30 min before fixation and permeabilization with Perm/Fix
solution (eBioscience, Paris). Cells were finally labelled with anti-IL-10, anti-IL-17, and anti-
IFN-γ antibodies (BD Biosciences, Le Pont-de-Claix). Samples were analysed on a FACS Canto
II and the analysis performed using the BD FACSdiva software (BD Biosciences).
Statistical analysis
Statistical analysis was performed with GraphPad Software (San Diego, CA). Comparison be-
tween groups used the Shapiro-Wilk normality test. When groups passed normality test, an un-
paired t test was performed; otherwise, a Mann-Whitney test was used.
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Results
hASCs reduce the clinical score and the inflammatory response of
arthritic mice
We first aimed at investigating the effect of hASCs in a model of severe and systemic inflamma-
tion in the collagen-induced arthritis (CIA) model. We evaluated two therapeutic strategies.
The first one consisted of injecting hASCs at day 18 and day 24 just before the onset of CIA
and at the very beginning of joint inflammation (prophylactic approach). In this model, hASCs
efficiently reduced the arthritis symptoms for at least 20 days (Fig. 1A). Although the aim of
the present study was not to determine precisely the mechanisms by which hASCs exerted
their effect, we quantified the variations of the different T lymphocyte subsets in response to
the treatment. We found a decrease of the number of CD4+IFN-γ+ Th1 cells and CD4+IL-17+
Th17 cells in the spleens of hASC-treated mice as compared to CIA mice (Fig. 1B). The same
tendency was also observed in the lymph nodes of hASC-treated mice (data not shown). We
also noticed a significant increase of CD4+IL-10+ Tr1-like lymphocytes in lymph nodes (Fig. 1B).
The second strategy was to inject the hASCs after the onset of arthritis when mice reached an
arthritic score between 2 and 4 (therapeutic approach). Using this approach, we also recorded a
significant reduction of arthritic scores in hASC-treated mice for at least 10 days, although to a
lesser extent than that observed when cells were injected before onset. In concordance with previ-
ous data using hASCs or hMSCs from amniotic membrane or umbilical cord [13, 16, 17], these
data therefore confirmed that hASCs can exert their anti-inflammatory function in arthritic mice.
Short-term persistence of hASCs after intravenous injection was not
related to the inflammatory status of the mice
We determined the persistence and biodistribution of hASCs in arthritic mice that received the
hASCs at disease onset, when the inflammatory response of the host is already very high and
the therapeutic effect of hASCs more modest (therapeutic approach). At day 1 after IV admin-
istration in normal or CIA mice, hASCs were detected in the lungs in 10/10 injected mice
(Fig. 2A). Cells were not detected in the other 12 organs. No significant difference in the per-
centage of hASCs present in the lungs was measured in normal (47.6 5.9%) or arthritic
(66.4 6.9%) mice at that time point although some tendency to higher cell number in CIA
mice was observed (Fig. 2B). At day 10, hASCs could not be detected in arthritic or normal
animals. Although we could not evaluate the survival rate of cells between day 1 and 10, the
data suggested that high levels of systemic inflammation did not affect the survival of hASCs
as compared to normal conditions while their anti-inflammatory function contributed to re-
ducing the arthritic symptoms.
hASCs efficiently decrease the OA score after intra-articular injection in
the CIOA mice
We then aimed at evaluating the effect of hASCs in the CIOAmodel where a local moderate in-
flammation of the synovial membrane is reported. In this model, we previously described that
the injection of murine ASCs significantly decreased the OA score [12]. We therefore deter-
mined whether hASCs may exert a similar effect after injection in the knee joints of mice at day
7 after CIOA induction. Histological analysis revealed a decrease of the OA scores in both later-
al and medial compartments of the joints with significantly reduced scores in the median
femur condyles and tibial plateaux 35 days after hASC implantation (Fig. 3A). Representative
photographs of knee joints illustrated the high rate of degradation of articular cartilage in
CIOA mice with depletion in safranin O-stained proteoglycans and cartilage erosion whereas
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protection of cartilage degradation was noticed in the ASC-treated mice (Fig. 3B). Concomi-
tantly, a reduction of systemic inflammation as measured by the levels of alarmin S100A9 and
MCP-1 in the sera of treated mice was observed at euthanasia (Fig. 3C). MIP-1A, RANKL and
IL-1β were not detected in the sera of mice (data not shown). We therefore showed for the first
time that hASCs are efficient at reducing the OA clinical scores in the CIOA model by decreas-
ing synovial inflammation.
hASCs administered by intra-articular injection were detected for at least
10 days in osteo-arthritic knee joints
We investigated whether hASCs may be detected in the joints of CIOA mice at different time
points after implantation and whether the persistence and biodistribution of hASCs were al-
tered in the CIOA model as compared to normal mice. We observed the presence of hASCs in
the joints of 10/10 and 3/10 of ASC-treated normal mice at day 1 and 10, respectively (Fig. 4A).
We also identified hASCs in the Tibialis anteriormuscle of one mouse at day 1 after cell admin-
istration. In CIOA mice, hASCs were detected exclusively in the joints at both time points
Figure 1. Effect of IV injection of hASCs in the CIAmousemodel. (A) Arthritic score for hind and fore paw
swelling at different time points during the course of the disease when hASCs were infused before disease
onset (preventive approach). Arrows indicate the days of hASC injection. (B) Percentage of Th1 lymphocytes
(CD4+IFN+), Th17 lymphocytes (CD4+IL17+) in spleens and Tr1 regulatory lymphocytes (CD4+IL10+) in
lymph nodes of CIA and hASC-treated CIA mice. (C) Representative histological pictures of ankle joints from
CIA (left) and hASC-treated CIA mice (right). (D) Arthritic score for hind and fore paw swelling at different time
points during the course of the disease when hASCs were infused at disease onset (therapeutic approach).
Results are expressed as the mean SEM (standard deviation of the mean), n = 8. *p<0.05, **p<0.01.
doi:10.1371/journal.pone.0114962.g001
Figure 2. Comparison of the biodistribution of hASCs after IV administration in normal or CIA mice.
(A) Percentage of mice in which hASCs were detected in the lungs or 12 other independent organs at day 1
after IV injection. (B) Percentage of hASCs detected in lung relative to the number of initially injected hASCs
in normal or CIA mice. Results are expressed as the percentage of hASCs as evaluated by Alu sequence
quantification and normalization using serial dilution of hASCs in murine MSCs SEM (standard deviation of
the mean).
doi:10.1371/journal.pone.0114962.g002
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indicating absence of migration to other organs (Fig. 4B). Interestingly, no differences in the
percentage of hASCs present in the joints of normal and CIOA mice were noticed, with respec-
tively 60.5 3.9% and 70.3 4.7% at day 1 and 7.9 4.3% and 8 4.2% in the total group of
mice at day 10 (Fig. 3B). At day 30, no cell could be detected in normal or CIOA mice. These
data demonstrated that local moderate inflammation does not affect the persistence of cells. They
moreover confirm that the therapeutic effect of the cells lasted, also after hASC disappearance.
Figure 3. Effect of IA injection of hASCs in the CIOAmousemodel. (A) OA score for cartilage destruction
at 4 different locations in the knee joint, i.e., the lateral tibia plateau (LT), lateral femur condyle (LF), medial
femur condyle (MF), and medial tibia plateau (MT) at euthanasia. (B) Representative photographs of knee
joints from CIOA (left) and hASC-treated CIOA mice (right). (C) MCP-1 and S100A9 alarmin concentrations
were determined in sera of mice at euthanasia by specific sandwich enzyme-linked immunosorbent assay
(ELISA). Results are expressed as the mean SEM (standard deviation of the mean), n = 8. *p<0.05,
**p<0.01.
doi:10.1371/journal.pone.0114962.g003
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Figure 4. Comparison of the biodistribution of hASCs after IA administration in normal or CIOAmice.
(A) Percentage of normal mice in which hASCs were detected in the joints or 12 other organs after IA injection
at day 1 or 10. (B) Percentage of normal or CIOAmice in which hASCs were detected in the joints or muscle
(others) after IA injection at day 1 or 10. (C) Percentage of hASCs detected in the joint relative to the number
of initially injected hASCs in normal or CIOA mice. Results are expressed as the percentage of hASCs as
evaluated by Alu sequence quantification and normalization using serial dilution of hASCs in murine MSCs
SEM (standard deviation of the mean).
doi:10.1371/journal.pone.0114962.g004
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Discussion
These data are the first to present the persistence and biodistribution of hASCs after IV or IA
injection in arthritic immunocompetent mice, using large scale analysis on 13 different tissues
or organs. The important finding of the present study is that inflammation, and notably the de-
gree of inflammation, does not affect the persistence of hASCs as evaluated in two pre-clinical
mouse models of arthritis.
Persistence and biodistribution of hASCs are important parameters to evaluate for safety
and determination of local interaction and function of cell therapy products. We relied on the
quantification of the human specific Alu sequences by PCR, which allows high sensitivity of de-
tection of implanted cells without genetic modification or labeling of the cells as previously re-
ported [9]. Although it may be assumed that the number of cells detected in organs is a rough
approximation of what is quantified using serial dilution of cultured cells, the approach allowed
a long-term follow-up on several organs. In this previous study, we investigated the biodistri-
bution of hASCs in the SCID/Bg immunodeficient mice [9]. In these conditions, we mimicked
autologous cell implantation due to the absence of functional B and T lymphocytes but more
likely to the absence of NK cells, which are known to efficiently lyse MSCs [18]. A high number
of cells had been injected in order to evaluate the safety of clinical grade hASCs, in particular
for tumour formation. We demonstrated long-term survival of hASCs (at least 6 months) after
IA injection in 60% of the injected mice and noticed the migration of hASCs to some organs,
notably muscle, bone marrow and adipose tissue [9]. In the present study, absence of hASC mi-
gration to other organs was observed, with the exception of one mouse with cells in the Tibialis
anteriormuscle. Although these differences in migratory profile may be attributed to the im-
munological status of the mice, they are more likely due to the doses of injected cells, which
were 4-fold less than that used in the previous study.
Another difference between these two studies performed in normal mice was the number
of cells detected at the same time points. At day 10 in immunocompetent mice, no hASC was
observed after IV injection while 8% of hASCs could be detected in the knee joint. By com-
parison, 1.1% and 12% of hASCs were detected respectively, in lungs and knee joints of im-
munodeficient mice [9]. At day 30, hASCs were exclusively detected in immunodeficient
mice after IA administration. In the joint, hASCs home to the synovial membrane which
constitutes a MSC niche [19] and likely a favourable environment for exogenous MSCs.
Moreover, the joint space is a restricted environment that mechanically favours cell reten-
tion. In accordance, detection of nanoparticle-labelled allogeneic MSCs was also reported
up to 7 days following IA injection in another arthritic model [20]. Injection of autologous/
syngeneic MSCs allowed persistence for similar or longer periods depending on the OA mod-
els used. It fluctuated between 7 days in the mouse model to 2 weeks in rat and 20 days in the
rabbit model [12, 21, 22]. Variation in survival time of MSCs in these models may be related
to the number of injected cells but also to the sensitivity of the detection method, relying on
in vivo luciferase or immunohistochemistry detection. Rapid clearance of hASCs after IV in-
jection was expected by reference to the previous study by Prockop and collaborators who re-
ported a half-life of 24h [23]. Such rapid cell elimination was not observed after IV infusion
of allogeneic MSCs, which were completely rejected after a longer period of 40 days [24]. Al-
though the present study did not aim at evaluating cell rejection but rather cell persistence,
one could hypothesize that rapid clearance of hASCs is likely to be due to an enhanced host
immune response, characterized by detection of interspecies differences in the expression of
surface markers and major histocompatibility complex antigens I and II (MHCII). We there-
fore confirm a longer persistence of hASCs after IA injection and a more rapid disappearance
of cells in immunocompetent animals.
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Besides comparing the behavior of hASCs in normal mice, the major objective of the study
was to investigate whether an inflammatory environment may alter the persistence and distri-
bution of hASCs in vivo, with a possible effect on the therapeutic efficacy of the cells. We used
the preclinical CIOA and CIA models of the most prevalent rheumatic diseases, OA and RA re-
spectively. Both models are mouse strain—dependent and characterized by inflammation,
which is moderate in CIOA and severe in CIA [25]. Efficacy of allogeneic MSCs or xenogeneic
hASCs has already been shown in CIA using both preventive and curative approaches, even
though some studies report absence of therapeutic benefit likely related to the types of MSCs
used [13, 26, 27]. However, efficacy of hASCs was not documented in osteoarthritis models.
Using the CIOA model, we showed that hASCs could reduce cartilage degradation of the knee
joint and decrease the level of systemic inflammatory mediators demonstrating that hASCs
exert a protective effect for at least 35 days. We previously reported that IA administration of
syngeneic mMSCs protected against cartilage destruction for a similar period of time [12]. We
also showed that mMSCs expressing the GFP marker had disappeared at day 5 after injection.
In the present study, hASCs were still detected at day 10. This may be due to the higher number
of injected cells (10 fold more) or to the sensitivity of the detection method. In both models,
the beneficial effect of MSCs was observed for a long period of time, when cells were no longer
detectable. This was recently referred to the hit-and-run mechanism of MSCs where treatment
efficacy was not correlated with engraftment duration [28]. However, the question of hASC
persistence in a pathological context of inflammation is still poorly answered.
The interesting finding of the present work is that inflammation, which is expected to prime
hASCs and up-regulate the expression of immunosuppressive factors, did not affect their sur-
vival or biodistribution. First, biodistribution of hASCs was not altered by inflammatory sig-
nals. hASCs were retained in the target organs, respective to the route of injection. In the CIA
model, a possible migration of hASCs towards the knee joint, which is one of the main in-
flamed joints, was not observed. One potential explanation may be related to the time of analy-
sis (day 1) or the tissue origin of the cells since after initial concentration in the lungs, bone
marrow-derived MSCs have been shown to migrate to injured tissues within 2 to 7 days [23,
29]. However, others report that after 24h, MSC are relocated to other organs while a strong
decrease in viability is observed (for review, see [29]). Although we cannot exclude that hASCs
had migrated to the joints or other organs at later time points or, that the short survival of cells
did not allow the visualization of migratory hASCs at day 10, it is likely that most of the cells
rapidly disappeared from lungs. Second and more importantly, survival of hASCs was identical
in normal and arthritic mice, as shown by the same number of hASCs detected in the targeted
organs, lungs and knee joints in CIA and CIOA respectively. There is now consensus that
MSCs are not immune privileged and a number of studies have provided evidence that mis-
matched MSCs can induce anti-MSC immune responses. They are nevertheless more slowly re-
jected by the host immune response than other cells and this is dependent on the balance
between the expression of immunogenic and immunosuppressive factors by MSCs (for review,
see [30]). This implicitly suggests that priming of MSCs by the inflammatory milieu should be
required to up-regulate the immunosuppressive factors and enhance their capacity to escape
rejection. Accumulating evidence suggests that MSCs can trigger the induction of regulatory
T cells or macrophages that may account for their immunoregulatory properties but are short-
lived cells in vivo [31]. Our results clearly indicate that hASCs were not protected from elimina-
tion when present under moderate or severe inflammatory environment. Indeed, while inflam-
matory signals are required for the immunosuppressive function of MSCs, they do not
enhance their capacity to survive in vivo.
In conclusion, a number of studies have already investigated the survival and biodistribution
of BM-MSCs or ASCs after implantation in different locations, mostly in autologous situations.
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However, most of the studies did not take into account the pathological environment of the
disease itself. In the present study, we report that persistence and biodistribution of hASCs is
dependent on the route of administration independently of the immune status of the animals.
The important information is that neither inflammation nor the degree of inflammation influ-
ences the persistence of hASCs. These findings might have implications in the practical use of
MSCs, both in the context of preferred route of administration or state of inflammation in cell
activation or rejection.
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